Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Recruiting Observational Study
Focal Segmental Glomerulosclerosis Minimal Change Disease FSGS MCD
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
300 (estimated)
Sponsor
University of Michigan · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry st…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Retrospective non-consented participant group had a transplant from the year 2000 and onward. * Diagnosis of FSGS or MCD in the native kidney (prior to transplant). Exclusion Criteria: * Pathologic diagnosis other than FSGS or MCD * FSGS or MCD secondary to a known disorder …
Contacts

Ashley Rahimi

734-647-5446

asboggs@med.umich.edu

CONTACT

Eloise Salmon, MD

734-936-4210

salmonel@med.umich.edu

CONTACT